menu search

ALLK / Why Allakos Stock Sank 17.3% in February

Why Allakos Stock Sank 17.3% in February
The biotech stock has lost roughly 96% of its value over the last year. Read More
Posted: Mar 7 2022, 10:39
Author Name: The Motley Fool
Views: 092010

ALLK News  

Why Shares of Allakos Are Up Wednesday

By The Motley Fool
September 27, 2023

Why Shares of Allakos Are Up Wednesday

An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders. more_horizontal

Scratching The Surface: Allakos' Novel Take On Urticaria

By Seeking Alpha
September 18, 2023

Scratching The Surface: Allakos' Novel Take On Urticaria

Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirenteli more_horizontal

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

By Seeking Alpha
May 21, 2023

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74 more_horizontal

Why Allakos Stock Skyrocketed Nearly 9% Higher Today

By The Motley Fool
May 12, 2023

Why Allakos Stock Skyrocketed Nearly 9% Higher Today

An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech. more_horizontal

Why Allakos Stock Was Heating Up Today

By The Motley Fool
March 7, 2023

Why Allakos Stock Was Heating Up Today

Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the more_horizontal

Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade

By Zacks Investment Research
December 9, 2022

Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade

Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Why Allakos Stock Sank 17.3% in February

By The Motley Fool
March 7, 2022

Why Allakos Stock Sank 17.3% in February

The biotech stock has lost roughly 96% of its value over the last year. more_horizontal

Why Allakos Stock Sank 17.3% in February

By The Motley Fool
March 7, 2022

Why Allakos Stock Sank 17.3% in February

The biotech stock has lost roughly 96% of its value over the last year. more_horizontal


Search within

Pages Search Results: